Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Book

Lytic Bone Lesions

In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan.
.
Affiliations
Book

Lytic Bone Lesions

Surabhi Subramanian et al.

Excerpt

Bone tumors are mostly benign. The most important determinants in imaging of bone tumors are morphology on plain radiograph (well-defined lytic, ill-defined lytic, and sclerotic lesions) and age of the patient at presentation. Well-defined osteolytic bone tumors and tumor-like lesions have many differentials in different age groups. For simplicity, a widely used mnemonic for lytic bone lesions is extremely helpful: FEGNOMASHIC. We have attempted to describe the most characteristic features of each of these tumors. The different bone tumors and lesions discussed are as follows: fibrous dysplasia (FD), eosinophilic granuloma (EG), enchondroma, giant cell tumor (GCT), non-ossifying fibroma, osteoblastoma, aneurysmal bone cyst (ABC), solitary bone cyst (SBC), hyperparathyroidism (Brown tumor), infection (always kept in differential diagnosis while dealing with bone lesions), chondroblastoma, CMF, metastasis, myeloma (any bone lesion detected in 40 years and older, must be ruled out for metastasis and myeloma). The normal variant that can mimic lytic bone lesions is pseudocyst; this is an area of focal trabecular rarefaction at a low-stress region. Pseudocysts most commonly occur in the greater tuberosity of the humerus, calcaneus, and radial tuberosity. An osteolytic lesion with an ill-defined zone of transition is generally typical of malignant bone tumors (Ewing sarcoma, osteosarcoma, metastasis, leukemia) and aggressive benign lesions (giant cell tumor, infection, eosinophilic granuloma).

PubMed Disclaimer

Conflict of interest statement

Disclosure: Surabhi Subramanian declares no relevant financial relationships with ineligible companies.

Disclosure: Vibhu Krishnan Viswanathan declares no relevant financial relationships with ineligible companies.

References

    1. Lee JS, FitzGibbon EJ, Chen YR, Kim HJ, Lustig LR, Akintoye SO, Collins MT, Kaban LB. Clinical guidelines for the management of craniofacial fibrous dysplasia. Orphanet J Rare Dis. 2012 May 24;7 Suppl 1(Suppl 1):S2. - PMC - PubMed
    1. Hani R, Ben-Aissi M, Berrada MS. [Osteoblastoma of the ankle: an uncommon location]. Pan Afr Med J. 2018;29:164. - PMC - PubMed
    1. Resnick D, Cone RO. The nature of humeral pseudocysts. Radiology. 1984 Jan;150(1):27-8. - PubMed
    1. Weinstein LS, Shenker A, Gejman PV, Merino MJ, Friedman E, Spiegel AM. Activating mutations of the stimulatory G protein in the McCune-Albright syndrome. N Engl J Med. 1991 Dec 12;325(24):1688-95. - PubMed
    1. Bergovec M, Kubat O, Smerdelj M, Seiwerth S, Bonevski A, Orlic D. Epidemiology of musculoskeletal tumors in a national referral orthopedic department. A study of 3482 cases. Cancer Epidemiol. 2015 Jun;39(3):298-302. - PubMed

Publication types